New Generation Drug Discovery
Advanced analytical technologies have provided approaches in analyzing the bioactivities of single component drugs, but the complexity of chemical composition in multi-component
drugs makes it difficult in identifying the chemical and biological basis underlying the pharmacological actions. The pharmaceutical manufacturing is receiving more and more challenges today. The rising customer expectation makes the commercial
environment of healthcare providers gets harsher. Increasing wants of healthcare payers on new alternatives that are clinically and economically better than the current therapies imposes the new costs constraints on the pharmaceutical companies. On the other hand, unchanged discovery and developing process in finding novel alternatives over the past decades makes the scientific productivity be expected desirable. During the past years, the pharmaceutical manufacturing’s outputs remain stable and seems hardly to soar all of a sudden. As a result, the number of
approved new
molecules and biological licence applications by FDA is decreasing year by year. Compared with 1996, when 53 new molecular entities were approved, the number has been reduced to 19 in 2009. Pharmaceutical companies are suffering from a very low success rate in developing potential candidates that are screened from a large pool of chemical database, towards new drug products. New demands are required to be times of new generation of drug discovery and its analytical technologies.
High Impact List of Articles
Relevant Topics in Clinical